-+ 0.00%
-+ 0.00%
-+ 0.00%

REVOLUTION MEDICINES’ RAS(ON) MULTI-SELECTIVE INHIBITOR DARAXONRASIB GRANTED U.S. FDA ORPHAN DRUG DESIGNATION IN PANCREATIC CANCER

Reuters·10/27/2025 12:00:04

Please log in to view news